This study will determine the safety and efficacy of moving to a second-generation manufacturing process using the CliniMACS Prodigy platform to manufacture hu…

B Cell Acute Lymphoblastic Leukemia (B-ALL)B Lineage Lymphoblastic Lymphoma

~Estimated

~$10 – $7,500

Stephan Grupp MD PhDNCT05480449

Phase 1

Use of Autologous Anti-CD22 CAR T Cells (CART22-65s) Co-administered With Humanized Anti-CD19 CAR T Cells (huCART19) in Children and Young Adults With Relapsed or Refractory B-ALL

This study will evaluate the safety and efficacy of administering two CAR T cell products, huCART19 and CART22-65s, in children with advanced B cell Acute Lymp…

B-cell Acute Lymphoblastic LeukemiaB Lineage Lymphoblastic Lymphoma

~Estimated

~$10 – $7,500

Stephan Grupp MD PhDNCT05674175